Cite
Kumar S, Zeng Z, Bagati A, et al. CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells. Cancer Discov. 2021;11(8):2050-2071doi: 10.1158/2159-8290.CD-20-1144.
Kumar, S., Zeng, Z., Bagati, A., Tay, R. E., Sanz, L. A., Hartono, S. R., Ito, Y., Abderazzaq, F., Hatchi, E., Jiang, P., Cartwright, A. N. R., Olawoyin, O., Mathewson, N. D., Pyrdol, J. W., Li, M. Z., Doench, J. G., Booker, M. A., Tolstorukov, M. Y., Elledge, S. J., Chédin, F., Liu, X. S., & Wucherpfennig, K. W. (2021). CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells. Cancer discovery, 11(8), 2050-2071. https://doi.org/10.1158/2159-8290.CD-20-1144
Kumar, Sushil, et al. "CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells." Cancer discovery vol. 11,8 (2021): 2050-2071. doi: https://doi.org/10.1158/2159-8290.CD-20-1144
Kumar S, Zeng Z, Bagati A, Tay RE, Sanz LA, Hartono SR, Ito Y, Abderazzaq F, Hatchi E, Jiang P, Cartwright ANR, Olawoyin O, Mathewson ND, Pyrdol JW, Li MZ, Doench JG, Booker MA, Tolstorukov MY, Elledge SJ, Chédin F, Liu XS, Wucherpfennig KW. CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells. Cancer Discov. 2021 Aug;11(8):2050-2071. doi: 10.1158/2159-8290.CD-20-1144. Epub 2021 Mar 11. PMID: 33707234; PMCID: PMC8338742.
Copy
Download .nbib
